🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Zimmer Biomet Holdings, Inc. (ZBH)
NYSE: ZBH · Real-Time Price · USD
101.10
-0.37 (-0.36%)
At close: Nov 20, 2026, 4:00 PM EST
100.82
-0.28 (-0.28%)
After-hours: Nov 20, 2026, 7:30 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 19, 2026

Summary

2026 performance exceeded expectations through three quarters, with strong growth in hips, SET and technology offset by softer knees. Management expects 2027 growth to improve, supported by China, innovation and commercial execution, and targets 6% WAMGR by 2030.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

I'm ready to go. Thanks, everybody, for joining us this afternoon. I'm Matt Taylor, the U.S. Medical Supplies and Devices Analyst here at Jefferies, and I'm pleased to be joined by Zimmer management, including Ivan Tornos, the CEO, and Paul Stellato, the Interim CFO. Thanks, guys, for coming. We'll have about 25 minutes for a fireside chat Q&A. Ivan, I just want us to start maybe by talking about your performance year- to- date.

Over the past few years, we've seen a lot of progress, I think, on the vitality of the portfolio and the innovation, and that's starting to show. You have these three strategic pillars that you talk about: people and culture, operational excellence, and innovation diversification. Maybe just touch on the performance and talk about how you're making progress on the three pillars.

Ivan Tornos
CEO, Zimmer Biomet

Yeah, absolutely. Thanks, Matt, and thanks, everybody, for joining. I guess the headline for the year 2026 so far is that performance is above expectations. Three quarters behind, we delivered above expectations for all three quarters. In terms of the three priorities, for now three years that I've been the CEO, I've spoken about the three key priorities of the company. Number one, people and culture. Number two, operational excellence. Number three, innovation and diversification. I'll highlight a couple of things in those three priorities. On people and culture, which is paramount, foundational to everything that we do, I'm very pleased with where we're at.

This last October, we completed another engagement survey for the organization. We achieved the highest engagement scores in the history of the company. We've been recognized by the likes of Forbes, Fortune, Time Magazine as one of the best employers, not just in the U.S., but globally. From an innovation standpoint, we continue to get recognized as one of the fastest innovators in the space. A lot that I could say about people and culture, but all the right metrics, high engagement, low turnover, and again, getting a lot of external sources validating that what we do from a people and culture is strong. On operational excellence, we'll close this year generating close to $2 billion in operating cash flow, roughly $1.3 billion, $1.4 billion in free cash flow.

Our free cash flow conversion is the highest in the last 11 years at almost 80%. We continue to do all the right things when it comes to addressing the inefficiencies of the business, and again, the data suggests that we're moving in the right direction. A lot of work is still ahead, but making progress at a very fast pace. Innovation and diversification, which we spoke about in the third earnings, in the third quarter call. 2/3 of the book of business, Zimmer Biomet, are growing upper single digit or double digit. I think that's the outcome of all the great work we've done over the last five years. Our WAMGR five years ago was 2.75%, close to 3% .

Our WAMGR today, weighted average market growth rate, is 4.25%. We've made investments in technology like Paragon 28. We've done three, five acquisitions in SET. We divested spine and dental. We shifted all the R&D of the company into higher growth projects. We're looking at different ways to do R&D. I do not want to ramble too much for the answer, but the fact that today 2/3 of Zimmer Biomet are growing upper single digit, if not double digit, tells you that we are diversifying and we are innovating at the right pace. So more to come, but the word used is progress, and progress we are making.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. Maybe we could also unpack Q3 a little bit. You had a strong quarter with some moving parts. Could you talk a little bit about the strength in hips and SETs and what we used to call other, but now it is data and technology? You had a little bit of softness in knees, and maybe you could also talk about how the tuck-ins contributed to the quarter.

Ivan Tornos
CEO, Zimmer Biomet

Sure. Maybe we will start with the tuck-ins. So we acquired three platforms over the summer that they happen from a timing standpoint to get integrated in the third quarter of 2026. These are immaterial to the growth of the company. That is why the disclosure is the disclosure that we did in the 10-Q. Those three platforms are iovera° , iovera° is a platform for management of pain by what is called cryoneurolysis. So cryoneurolysis basically is freezing the nerves around your knee that are inducing the pain. We love this platform because it is highly scalable. Under the NOPAIN Act in the United States, it is going to get a lot of traction.

It is already getting a lot of traction. It will get federal reimbursement at some point, and again, it is a great point of entry for those patients that down the road are going to have to get a knee replacement. So that is iovera°. Then we acquired a platform called Monteris for neuro disorders, highly synergistic with our CMFT business. This is for brain tumors, epilepsy, highly complementary with the work we do already with ROSA Brain. We are the number one company in the diagnosis of epilepsy through ROSA Brain.

So again, very excited about the opportunity here, [in-silico lab] Then the third one is Alafair, which is a company that does biosurgicals, a platform in biosurgicals, which again, is highly complementary to what we do in SET. So again, those three platforms we acquired late August, most of those, again, immaterial for the quarter, but tremendous potential down the road. In terms of the quarter, none of those three platforms, the quarter was solid. Again, repeating myself, 2/3 of the company growing upper single digit, double digit.

We saw hip performing very nicely, 7% growth in hips globally, 8.2% growth outside of the U.S., 5.8% in the U.S. We delivered one of the best performances in SET, delivering 7.1% global growth. Four of the six businesses grew upper single digit, double digit. Sports medicine, strong double digit, CMFT, 15%, foot and ankle, 18.4%. So everything working very nicely there. That is innovation, commercial execution, and the shift to the ASC space. Technology, you mentioned that we had a solid quarter. So we report technology, surgical, and other in one line. When you unpack that line, it is mostly technology. It is growing very nicely, 24% for the quarter. In the U.S., technology grew 34.6%.

So again, a lot of parts and pieces of the company are going very nicely. We got to do a better job with knees. It was not a surprise for us. We are making changes in the U.S. go-to-market model. This is having an impact in our U.S. knee franchise. That is why we declined 2%. Globally, 2.6% excluding China. We have actually been growing internationally, and excluding China, knee as a category would have been flat for the quarter. Nonetheless, we got work to do when it comes to our knee performance.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. Maybe in Q3 and recent quarters, there has been a lot of discussion about market growth, especially in the U.S., hips and knees. Could you talk about what you are seeing in the market, and have you observed any slowing? Could you characterize that a little bit for us?

Ivan Tornos
CEO, Zimmer Biomet

Sure. We continue to peg our weighted average market growth rate at 4.25% . We have never really broken into parts and pieces. Recon for the quarter was slightly softer than expected, 2.5%-3.5% in the U.S. Similar number of U.S., given all the noise here in Europe with the strikes, with the Middle East, again, pain in China for us, and other players are reporting some pain in China as well. But sum of all parts, the window remains 4.25% . Recon in the U.S., 2.5%-3.5%. Hips was very strong, as evidenced by the fact that we delivered 5.8% growth in U.S. hips. Knees, slightly choppier, but again, it has been a complicated year, Matt. We had the strikes with Kaiser at the beginning of the year.

We had the weather season that we had. We got a large competitor that's had all kinds of challenges in the year, and that impacts the market growth dynamic. We don't see any structural change when it comes to the market. We continue to look at leading indicators like cancellation rates, which remain the same for the last five years, waiting lists at the top 10 institutions in the United States. We look at referral cycles, from primary care over to orthopedics. Are we looking at the same timeframe? It's almost identical. There's nothing from a leading standpoint that tells us that we've seen something structurally that is going to change market growth rates in the future.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. I'd like to talk about some innovation here too. Maybe we could talk about Monogram a little bit. In Q3 call, you talked a little bit about the timelines shifting. Can you remind us of the timelines and what to expect from the launch here in 2027?

Ivan Tornos
CEO, Zimmer Biomet

Sure. Well, since we are in a public forum, I'm pleased to announce that we actually filed the 510(k) for Monogram this last Monday. The team told me it was ready on Friday, but as a Spaniard who's very superstitious, I didn't want to file on Friday, November 13th. We filed on Monday. Very exciting technology for the company. I got to be careful what I say here, because we got to get obviously the approval from the FDA. But we deem Monogram to be a game-changing platform when it comes to safety, efficiency, ease of use of the product, the actual reproducibility of the technology, and the accuracy.

Again, we filed the 510(k). It's a 90-day submission. We'll see where we land. I wouldn't be surprised if there's some back and forth with the FDA, given that this is a new-to-the-world technology. Our expectations are we're going to be launching in the year 2027. Our expectation is that we're going to be able to go straight into what we call a fully autonomous or surgeon-guided autonomy platform. If you recall, Matt, this is something we think we're going to be able to do around 2028, early 2028, maybe mid-2028 at one point. This is going to happen now dramatically sooner than that. Again, a very exciting announcement here.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Yeah, very exciting. You mentioned the safety, the efficiency. What are the aspects of Monogram you're most excited about?

Ivan Tornos
CEO, Zimmer Biomet

There's five things that we put in the clinical trial that we're very excited about. Number one is safety. This is truly smart technology that is able to identify when there's a potential risk to soft tissue injury. We did a robust clinical trial, and we reported zero safety events in that trial. On the efficiency side of things, again, got to be careful what I say. We got to get all this approved by the FDA. But faster registration, faster bone preparation, fast limb marking. This is not the kind of technology that slows the surgeon down. So very efficient, very fast, very scalable. One of the great inputs that we're getting from surgeons that have been exposed to the device, the platform, is the reproducibility.

This is the kind of device, the kind of robot, that once you've done a few cases, is highly reproducible. You don't need to change your surgical algorithm. We're going to come in with less instrumentation, simplified trays, so less inventory. So very easy to scale up. And then accuracy. Best-in-class accuracy versus what we have in the market today. So safety, efficiency, ease of use, reproducibility, and accuracy. We believe that this is a robot that is going to gain great adoption. We're going to make sure that we validate everything that I'm saying here today, that we get the FDA claims that we aspire to get. We're going to do a thoughtful launch in 2027, assuming approval from the FDA, but we deem it game-changing.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. Another key topic, shifting gears, as you mentioned, the sales force transition. You're kind of midway through that. Maybe you could talk about the progress so far, signs that you're seeing that it's the right strategy, and if you're on track to complete it by the end of next year.

Ivan Tornos
CEO, Zimmer Biomet

Data is what I believe in, right? If you look at 2026 so far, with 28 working days left in the year, the U.S. is growing 3.8%. The U.S. net of knees is performing very nicely. We saw two consecutive quarters of very solid hip performance, double-digit growth in most categories in SET. Upper single-digit growth last quarter in hips, 5.8% this quarter. The data suggests that we are doing all the right things. Our turnover in the U.S. is at a five-year low, so we are reporting a turnover rate in the U.S. in the 4%-5% range. We are seeing a lot of interest in going into Zimmer Biomet.

We have now changed 75% of the organization. We have 2,540 reps in the U.S. When we started the journey, most of them did not work for Zimmer Biomet. Today, 75% of these 2,540 reps work exclusively for Zimmer Biomet. We have one-fourth to go. Again, moving faster than we initially anticipated. The last fourth is the riskiest of all stages.

We are going to take our time. We are doing that as we speak. We are going to take the rest of the fourth quarter and on to 2027 to close this. Again, this is going better than anticipated. It is very well governed. We are investing time and money to make sure we are doing this thoughtfully, and so far, every metric on the dashboard that we constantly stare at is on the green. We like where we are at.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. Speaking of 2027, I know you are not going to do two firsts today here on the stage, but not guided 2027. I do want you to give folks some things to think about there, and also in the context of a 2026 where you took a little bit of a different tack with your guidance. How are you thinking about 2027 overall, and how are you thinking about the guidance?

Ivan Tornos
CEO, Zimmer Biomet

Yeah. I will stick to the public commentary that we have made. We said, and I will repeat it here today, that 2027 will be better from a growth perspective than 2026. Why would it not be, right? We got the China headwind. In 2026, our China business, which is 2% of revenue, 1% of EBITDA, cost us 50 basis points of growth. We are going through a consolidation of distributors. We have taken a lot of pain with volume-based procurement and whatnot. That anniversary is on January 1st, so we lost 50 basis points in 2026. We expect that we are going to get a tailwind in 2027.

All this transformation we are doing in the U.S. is starting to yield better results as we close the year 2026, and we see that continuing into 2027. Paragon 28, which has been a great acquisition, delivered 18.4% growth in the quarter, the third quarter. We are committed to growing this in the teens. We see this growing in the teens for a long while. in 2027, that is going to be an entire year. It goes into organic, so we benefit from having Paragon 28 for 12 months of the year. Expecting to get Monogram, ideally two to three quarters. We will see what the FDA says.

Beyond Monogram, there is a lot of exciting technology. We are seeing great success with ROSA Shoulder, one of the reasons why our shoulder performance was better than expected in the third quarter. Solid performance so far in the fourth quarter for ROSA Shoulder. That is going to be a full year of ROSA Shoulder in 2027. Those are kind of like the tailwinds as we think about 2027. Innovation, better commercial execution, of course, Monogram, and the China headwind. At the same time, look, we got to keep an eye on the last stage of this transformation in the U.S., right?

This is the riskiest, as we have been saying, so we need to monitor that, and we need to pay attention to some of the things that always happen in the business. That said, our guidance philosophy, say less and do more. We are going to be responsible in how we guide, especially right out of the gate, as we did in 2026. As always, we will try to do better than what we tell you, but we are going to follow a similar philosophy as the one we did here in 2026.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. Maybe we could double-click on M&A. You have been diversifying and moving into some strong adjacencies. You mentioned the Paragon performance has been really strong. Could you talk more about your M&A strategy from here? What are some of the key areas that you are looking to move into, and which ones make the most sense?

Ivan Tornos
CEO, Zimmer Biomet

Yeah. We have an ambition, which I believe is more of a goal than ambition, of having a WAMGR of 6% by 2030. That means that we got to generate 175 basis points of WAMGR accretion from the 4.25% today to 6%. We believe that we can do half of that through organic means. We shifted, as I mentioned earlier, our R&D to higher growth segments. We have done a lot of debt co-work with external parties. We got a great partnership with Deerfield that we expect to see some innovation that is going to be WAMGR accretive through that venture. So we believe that we can probably get 50% of the 175 basis points through organic means, and the rest we are going to have to do through full acquisitions.

So we are not going to do anything reckless. We have evidence through the Paragon 28 acquisition that we know how to identify, negotiate, and integrate deals. We look for deals that make strategic and financial sense. Those are higher growth segments within Recon, like iovera°, or what we've done with OrthoGrid. Deals that are going to be EPS neutral by year two. Deals that are going to deliver double-digit ROIC by year five. Beyond the high-growth segments of Recon, we look at anything that is growing in ASC.

We look at opportunities in SET. We love what we're doing in Neuro, our Neuro business as part of CMFT. When I joined the company, it was less than $100 million. That business is approaching $1 billion, growing double digit, our CMFT business is. There's a lot of opportunities in that space, so that's another strategic area. You're not going to get surprised. We're not going to do any deal that you're sitting there wondering why did Zimmer Biomet did this. We like where we are. We like the performance that we've seen. We're not going to do anything surprising to you.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. Another catalyst I think we should talk about is iodine, or as we say in [Philly] iodine. You launched in Japan with an iodine-coated hip. It's been doing—

Ivan Tornos
CEO, Zimmer Biomet

Is it iodine or iodine?

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

I don't know. But I wanted you to cover the progress there, maybe talk about the opportunity and other markets where you could go in with that.

Ivan Tornos
CEO, Zimmer Biomet

This has been a groundbreaking launch. Iodine, as we call it in the U.S. and in Spain, iodine here in the U.K. It took 12 years to bring this product to market, one of the most robust clinical trials ever undertaken in Japan. Japan is the second-largest market in the world in terms of revenue. The orthopedic market in Japan is $1.2 billion-$1.3 billion, growing at a nice clip, giving demographics, aging, and whatnot. The hip market in Japan is roughly $500 million , $500 million. And we're taking market share very, very, very quickly. And also, we benefit from a wall-to-wall dynamic, because every time you go from a non-iodine to an iodine-coated device, we get a 40% premium.

So, part of the reason why we delivered 7% growth this last quarter, 8.2% internationally, is because of this launch in Japan. Plenty of room to go in Japan, but as you can imagine, we are working closely now with the European Union to get the CE marking in the countries that make sense. Obviously, having a conversation with the FDA, exploring the opportunity in Canada. And you better believe it that we're going to move as fast as we can, responsibly but fast, in bringing iodine-coated technology to all the markets that make sense outside of Japan. Started with hips, we're going to move into knee and shoulder, and at some point, we believe that we'll have an entire category play for the iodine-coated devices.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Maybe you could just double-click and talk a little bit more about the adoption in Japan and what's really resonated with surgeons and how widespread it's become.

Ivan Tornos
CEO, Zimmer Biomet

Look, in the words of a Japanese surgeon that I spent time with three weeks ago in Tokyo, not using this product is malpractice. Periprosthetic joint infections are complex. Infection is the number one cause of readmission and going through a revision. The mortality rate associated with some of these infections actually is higher than breast cancer, melanoma, prostate cancer, and other types of melanoma. Yes, infection rates are low, 2%-3%, but once you get the infection, the mortality rates are actually quite high. Very costly for healthcare systems.

Again, quoting this Japanese surgeon, "It is malpractice not to use technology like iodine that actually is preventing the biofilm formation." Compelling data over 10, 12 years. That's why we've seen the rapid adoption that we've seen. That's why the Japanese PMDA designated this product a breakthrough technology. That's how you get the 40% premium on reimbursement, which we obviously transfer that onto pricing. The demand is very high. We supply as fast as we can. We're still enough suppliers getting to 2027. Talking of tailwinds for 2027, that's a major tailwind in 2027.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. Time we have left, maybe we should talk a little bit about margins. Maybe I'll start with gross margins. You've talked about some shifts in your manufacturing footprint. Maybe talk about the other revenue tailwinds and mix. How could those all play into gross margin expansion in the coming years?

Paul Stellato
Interim CFO, Zimmer Biomet

Sure. Yeah, and it's a good point. It's an area of focus that we have for the long term. The best way to get gross margin expansion for us is through the top-line growth, so we're making those investments, as you're aware of, things with the commercial channel, the investments we've made, acquisitions, et c, to drive that growth. We see that playing out over the long term. Getting into the cost side, there's really two principal things we're looking at, gross margin-wise. One is the footprint, right? We do, as you've seen, right, we produce in some of the highest-cost regions. We announced a shutdown in Switzerland a few weeks ago. We opened up a Costa Rica facility earlier this year.

You're going to start to see that shift happen, which again, will start to play out over the next couple of years, how that'll kind of flow through the P&L. Then there's SKU rationalization. We took a big charge at the end of last year to set us up for a much more kind of agile inventory profile, something that we haven't had in the past. We look forward to those both contributing for the long term, and we think sets us up pretty well for longer-term gross margin expansion.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. What about on the OpEx side? How should we think about OpEx levels for the rest of this year and next? What are some ways that you can get leverage on OpEx?

Paul Stellato
Interim CFO, Zimmer Biomet

Yeah. Yeah, good. I mean, again, the growth piece is certainly a part of that. I mean, there's a fixed cost base in there that we should be able to get leverage from. You heard Ivan quote it on the call, 46.5% OpEx is not a sustainable profile for us. It shouldn't be in this day and age. We've got some paths to get there. Technology is going to be a big enabler. We know we're very cautious because we know there's not an AI magic bullet that's out there. If you find the right use cases and you look at the areas where we've got some kind of higher fixed cost areas, we think there's going to be a great opportunity to drive consistent progress in those regions.

Then you've also got, we've got a global capability center that we've opened up in India. We've been able to shift some of our R&D resources there to get a little bit of a different profile, but with some great talent, right? There's some unbelievable talent in that region that we're able to kind of seed some different growth opportunities internally. A lot of work to do there. It's not easy. Nobody would tell you that it is. We're committed to it, and we look forward to driving some of those activities.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. Maybe I'll wrap up with a question on cash flow. Cash flow's been strong. Been using a lot of that. We talked about M&A, also buying back stock, and of course, these better margins could lead to more cash flow. Maybe you want to talk about how you've been able to improve cash flow thus far and the kind of progress that we could see in the coming years there.

Ivan Tornos
CEO, Zimmer Biomet

Well, we reduced our DOH dramatically over the last three, even now five years. At one point, our DOH was north of 100. Today, it's 365. We're not proud of that, but definitely much better than the 400 days. We still have way too many brands, our SKU rationalization program. Again, at one point, 1 million SKUs. We divested dental, we divested spine. We resized the number of knee and hip brands that we got. We did all the work we had to do geographically. We still have a tremendous opportunity ahead of us. We've done a lot of stuff around working capital. We've done a lot of stuff around portfolio. But it's still plenty of room to go.

Number one driver of free cash flow is revenue growth. I mean, this company, with innovation, with better commercial execution, can grow at a much faster pace, and all of that translates at some point to our cash flow. Then, the uses of cash flow, we're going to continue to prioritize having a stable dividend, doing strategic M&A, and when the stock is undervalued, which it is today, we are going to do buybacks. We'll do close to $500 million in buybacks in this fourth quarter, as we announced. That's where we are in terms of free cash flow and what we're doing.

Matt Taylor
U.S. Medical Supplies and Devices Analyst, Jefferies

Great. Well, that's a great place to end. Guys, thank you so much for your time, and thanks everybody for your interest in Zimmer Biomet.

Ivan Tornos
CEO, Zimmer Biomet

Thank you, Matt.

Paul Stellato
Interim CFO, Zimmer Biomet

Thanks.